Status:
NOT_YET_RECRUITING
Cilostazol for Prevention of Recurrent Stroke Trial
Lead Sponsor:
Stanford University
Collaborating Sponsors:
National Institute of Neurological Disorders and Stroke (NINDS)
Yale University
Conditions:
Stroke Recurrence
Myocardial Infarction
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.
Eligibility Criteria
Inclusion
- Diagnosis of stroke or mini-stroke (also called TIA) within the last 180 days
- Currently taking aspirin or clopidogrel (not both) to prevent another stroke
Exclusion
- Had a spontaneous brain bleed within the last 2 years.
- Moderate to severe heart failure.
- Life expectancy is less than 6 months.
Key Trial Info
Start Date :
August 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2031
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT07174414
Start Date
August 1 2026
End Date
July 1 2031
Last Update
September 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Stanford, California, United States, 94305